Synergy Pharmaceuticals Announces Partial Exercise of Over-Allotment Option by Aegis Capital Corp.
05. Juni 2012 16:15 ET
|
Synergy Pharmaceuticals
NEW YORK, June 5, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the partial exercise of the...
Synergy Pharmaceuticals to Present Abstract at Digestive Disease Week 2012
15. Mai 2012 09:15 ET
|
Synergy Pharmaceuticals
NEW YORK, May 15, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...
Synergy Pharmaceuticals Announces Closing of Public Offering of 10,000,000 Shares of Common Stock
09. Mai 2012 16:15 ET
|
Synergy Pharmaceuticals
NEW YORK, May 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP),a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its...
Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of 10,000,000 Shares of Common Stock
04. Mai 2012 01:52 ET
|
Synergy Pharmaceuticals
NEW YORK, May 4, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the pricing of an...
Synergy Pharmaceuticals Inc. Announces Proposed Public Offering
03. Mai 2012 16:19 ET
|
Synergy Pharmaceuticals
NEW YORK, May 3, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today its intention, subject...
Synergy Pharmaceuticals Appoints Gail M. Comer, M.D. as Chief Medical Officer
02. Mai 2012 04:00 ET
|
Synergy Pharmaceuticals
NEW YORK, May 2, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases,...
Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide Phase II/III Trial in Chronic Idiopathic Constipation
09. April 2012 07:15 ET
|
Synergy Pharmaceuticals
NEW YORK, April 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...
Synergy Pharmaceuticals to Present at AACR
26. März 2012 07:30 ET
|
Synergy Pharmaceuticals
NEW YORK, March 26, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that a poster...
Synergy Pharmaceuticals to Present at the Maxim Group Growth Conference
21. März 2012 07:30 ET
|
Synergy Pharmaceuticals
NEW YORK, March 21, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases,...
Synergy Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Financial
15. März 2012 19:06 ET
|
Synergy Pharmaceuticals
NEW YORK, March 15, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...